New York, USA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Charcot-Marie-Tooth Disease Market Size and Share to Grow by 2032, Predicts DelveInsight | Key Players in the Market - Pharnext, MedDay, HELIXMITH, ENCell, InFlectis, Addex, Augustine, DTx Pharma
The increase in the Charcot-Marie-Tooth disease market size is a direct consequence of increasing prevalent population of Charcot-Marie-Tooth disease patients in the 7MM.
DelveInsight’s Charcot-Marie-Tooth Disease Market Insights report includes a comprehensive understanding of current treatment practices, Charcot-Marie-Tooth disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Charcot-Marie-Tooth Disease Market Report
- As per DelveInsight’s analysis, the Charcot-Marie-Tooth disease market size in the 7MM was found to be ~USD 56 million in 2022 and it is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight’s estimates, total prevalent population of Charcot-Marie-Tooth disease in the 7MM was ~265K in 2021.
- Globally, leading Charcot-Marie-Tooth disease companies such as Pharnext SA, MedDay Pharmaceuticals, HELIXMITH, ENCell, Chong Kun Dang Pharmaceutical, InFlectis BioScience, Addex Therapeutics, Augustine Therapeutics, DTx Pharma, and others are developing novel Charcot-Marie-Tooth disease drugs that can be available in the Charcot-Marie-Tooth disease market in the coming years.
- Some of the key therapies for Charcot-Marie-Tooth disease treatment include PXT3003, MD1003, and others.
Discover which therapies are expected to grab the major Charcot-Marie-Tooth disease market share @ Charcot-Marie-Tooth Disease Market Report
Charcot-Marie-Tooth Disease Overview
Charcot-Marie-Tooth disease (CMT), named after the three physicians who first described it in 1886, is a group of inherited neurological disorders that affect the peripheral nerves. These nerves control muscle movement and relay sensory information to the brain. CMT is one of the most common inherited neurological disorders, with various subtypes, and its severity can vary widely among individuals. CMT is primarily caused by genetic mutations that affect the structure and function of peripheral nerves. These mutations can disrupt the normal production and maintenance of myelin, the protective sheath surrounding nerve fibers, or damage the nerve fibers themselves.
CMT manifests with a range of symptoms, the most common being muscle weakness and wasting, particularly in the lower legs and feet. Individuals with CMT often experience difficulty walking, frequent tripping or falling, and may have a high arch in their feet or foot deformities like hammer toes. Sensory symptoms such as numbness, tingling, and reduced sensation in the extremities are also common. In more severe cases, individuals may have difficulty with fine motor skills and experience muscle cramps and pain.
Diagnosing CMT typically involves a combination of clinical evaluation, family history assessment, and genetic testing. A neurologist may conduct a thorough neurological examination, assessing muscle strength, reflexes, and sensation. Electromyography and nerve conduction studies can help determine nerve function and identify the specific subtype of CMT. Genetic testing can confirm the presence of known CMT-related gene mutations.
Charcot-Marie-Tooth Disease Epidemiology Segmentation
The Charcot-Marie-Tooth disease epidemiology section provides insights into the historical and current Charcot-Marie-Tooth disease patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The Charcot-Marie-Tooth disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Charcot-Marie-Tooth Disease Prevalent Cases
- Charcot-Marie-Tooth Disease Diagnosed Prevalent Cases
- Charcot-Marie-Tooth Disease Gender-specific Diagnosed Prevalent Cases
- Charcot-Marie-Tooth Disease Age-specific Diagnosed Prevalent Cases
- Charcot-Marie-Tooth Disease Type-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Charcot-Marie-Tooth disease epidemiology trends @ Charcot-Marie-Tooth Disease Epidemiological Insights
Charcot-Marie-Tooth Disease Treatment Market
Charcot-Marie-Tooth disease has no cure and no recognized methods for treatment. The present CMT therapeutic market is built on supportive and symptomatic management, such as occupational therapy, physiotherapy, ankle-foot orthotics (AFO), and shoe inserts. The most prevalent form of assistance is physiotherapy, which is followed by foot care and occupational therapy. In approximately 30% of all identified cases, foot surgery for rectification of foot abnormalities remains a last choice. Pharmacotherapies mostly consist of pain relievers that assist lessen joint or muscular pain caused by the strains placed on the body by CMT or neuropathic pain caused by nerve damage. Tricyclic antidepressants (TCAs) or anti-convulsant medications can be used to treat neuropathic pain.
It is critical to maintain mobility, flexibility, and muscle strength. Starting a treatment program early may help to delay or minimize nerve degeneration and muscular weakness before it becomes a handicap. Muscle strength training, muscle and ligament stretching, and moderate aerobic activity are all part of physical therapy. A doctor-approved customized fitness regimen can help develop stamina, increase endurance, and preserve general health.
Many people with CMT need ankle braces and other orthopedic equipment to stay mobile and avoid harm. Braces, which provide support and stability while walking or ascending stairs, can help prevent ankle sprains. High-top shoes or boots can also provide support for weak ankles. Thumb splints can aid with hand weakness and fine motor skills loss. Assistive devices should be utilized before disability develops since they can avoid muscle strain and weakness.
To know more about Charcot-Marie-Tooth disease treatment, visit @ Charcot-Marie-Tooth Disease Treatment Drugs
Key Charcot-Marie-Tooth Disease Therapies and Companies
- PXT3003: Pharnext
- MD1003: MedDay Pharmaceuticals
Learn more about the FDA-approved drugs for Charcot-Marie-Tooth disease @ Drugs for Charcot-Marie-Tooth Disease Treatment
Charcot-Marie-Tooth Disease Market Dynamics
The dynamics of the Charcot-Marie-Tooth disease market are anticipated to change in the coming years. The growing global population is projected to result in an increase in treatment alternatives, and as a result, the Charcot-Marie-Tooth disease market will grow in the next years. In addition, an increase in public knowledge of genetic disorders will create a significant boost in the Charcot-Marie-Tooth disease market. Moreover, the lack of approved therapeutic options presents a significant opportunity for investment and development of innovative medicines. The present unmet need of the CMT disease market is for medications with improved safety and effectiveness that give an optimal cure.
However, several factors may impede the growth of the Charcot-Marie-Tooth disease market. A lack of comprehension of the clinical course and clinical relevance may represent a wasted chance to make the proper and early diagnosis. The potential of developing therapeutics may be limited by challenging diagnostic procedures, as patients frequently do not perform all essential diagnostic tests due to relatively high prices. In addition, long diagnostic procedures frequently result in delayed diagnosis and inadequate patient treatment, thus impeding Charcot-Marie-Tooth disease market growth. Furthermore, strict pricing and reimbursement policies will also impact on the Charcot-Marie-Tooth disease market growth.
| Charcot-Marie-Tooth Disease Report Metrics | Details |
| Study Period | 2019–2032 |
| Charcot-Marie-Tooth Disease Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Charcot-Marie-Tooth Disease Market Size in 2022 | USD 56 Million |
| Key Charcot-Marie-Tooth Disease Companies | Pharnext SA, MedDay Pharmaceuticals, HELIXMITH, ENCell, Chong Kun Dang pharmaceutical, InFlectis BioScience, Addex Therapeutics, Augustine therapeutics, DTx Pharma, and others |
| Key Charcot-Marie-Tooth Disease Therapies | PXT3003, MD1003, and others |
Scope of the Charcot-Marie-Tooth Disease Market Report
- Therapeutic Assessment: Charcot-Marie-Tooth Disease current marketed and emerging therapies
- Charcot-Marie-Tooth Disease Market Dynamics: Attribute Analysis of Emerging Charcot-Marie-Tooth Disease Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Charcot-Marie-Tooth Disease Market Access and Reimbursement
Discover more about Charcot-Marie-Tooth disease drugs in development @ Charcot-Marie-Tooth Disease Clinical Trials
Table of Contents
| 1. | Charcot-Marie-Tooth Disease Market Key Insights |
| 2. | Charcot-Marie-Tooth Disease Market Report Introduction |
| 3. | Charcot-Marie-Tooth Disease Market Overview at a Glance |
| 4. | Charcot-Marie-Tooth Disease Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Charcot-Marie-Tooth Disease Treatment and Management |
| 7. | Charcot-Marie-Tooth Disease Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Charcot-Marie-Tooth Disease Marketed Drugs |
| 10. | Charcot-Marie-Tooth Disease Emerging Drugs |
| 11. | Seven Major Charcot-Marie-Tooth Disease Market Analysis |
| 12. | Charcot-Marie-Tooth Disease Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Charcot-Marie-Tooth Disease Epidemiology Forecast
Charcot-Marie-Tooth Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Charcot-Marie-Tooth disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Charcot-Marie-Tooth Disease Pipeline
Charcot-Marie-Tooth Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Charcot-Marie-Tooth disease companies, including Pharnext SA, HELIXMITH, ENCell, Chong Kun Dang pharmaceutical, InFlectis BioScience, Addex Therapeutics, Augustine therapeutics, DTx Pharma, among others.
Alzheimer's Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer's Disease companies, including Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., among others.
Parkinson's Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others.
Psychosis in Parkinson’s and Alzheimer’s Disease Market
Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson’s and Alzheimer’s disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, among others.
Neurostimulation Devices Market
Neurostimulation Devices Market Insight, Competitive Landscape, and Market Forecast – 2028 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurostimulation devices companies, including Medtronic PLC, Cyberonics, Boston Scientific Corporation, Abbott Laboratories, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
